Bioventix PLC (LON:BVXP) price target raised to GBX 3,700 by FinnCap

Analyst Ratings For Bioventix PLC (LON:BVXP)

Story continues below

Today, FinnCap raised its price target on Bioventix PLC (LON:BVXP) to GBX 3,700 per share.

There are 0 Strong Buy Ratings, no Sell Ratings, no Hold Ratings, no Buy Ratings on the stock.

The current consensus rating on Bioventix PLC (LON:BVXP) is N/A with a consensus target price of GBX 3,700 per share, a potential .

Some recent analyst ratings include

      About Bioventix PLC (LON:BVXP)
      Bioventix PLC manufactures and supplies sheep monoclonal antibodies (SMAs) for use in blood-testing machines in hospitals and other labs worldwide. The company offers a portfolio of purified SMAs for thyroid, vitamin D, cardiac, drugs of abuse, fertility, infectious disease, oncology, and miscellaneous indications. It also provides contract SMAs and recombinant services. The company was founded in 2003 and is based in London, the United Kingdom.

      Recent Trading Activity for Bioventix PLC (LON:BVXP)
      Shares of Bioventix PLC closed the previous trading session at 828,00 up +228,00 6,33 % with shares trading hands.

      An ad to help with our costs